New Molecular Entities Approved In 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
You may also be interested in...
Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA
It looks to be a good bet that 2009 will mark a second year of growth in new drug approvals as FDA enters the second half of the year with a robust first-half NME approval tally and a well-stocked pipeline of novel agents with user fee goal dates in the remaining months of the year.
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals
FDA’s 2005 New Molecular Entity Total: 18, Including Five In December
FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.